CorMedix Inc. (CorMedix) is a biopharmaceutical company that focuses on in-licensing, developing and commercializing therapeutic products for the treatment of cardiac and renal dysfunction, also know as Cardiorenal disease. The Company has licensed all of the products in its Cardiorenal pipeline. The Company has several product candidates in clinical development, including its product candidates, CRMX003 (CorMedix Neutrolin), a liquid designed to prevent central venous catheter infection and clotting initially in dialysis catheters, and CRMX001 (the Company�s formulation of the drug deferiprone), which targets the prevention of contrast-induced nephropathy in patients.